Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (87)	12/9/2000 2:36:46 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 598

Tularik Bellies Up to the Cholesterol-Lowering Bar By Bradley J. Fikes December 8, 2000 Bringing a new drug into a market dominated by big pharmas is a lot like squeezing into a crowded, trendy nightclub: both require good connections or a lot of green. Tularik, a South San Francisco-based biotech, is trying to crash the hot field of cholesterol-lowering drugs. That field is now dominated by statins such as the ground-breaking Lipitor, Pravachol, and Zocor. These drugs have captured the hearts and prescription pads of cardiologists in just a few years, and they're backed by the marketing prowess of such companies as Pfizer, seller of Lipitor, and Merck, maker of Zocor. Whole story at doubletwist.com